Sharon Benzeno's most recent trade in Adaptive Biotechnologies Corp was a trade of 165,027 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 165,027 | 165,027 | - | - | Stock Option (right to buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 109,973 | 437,388 (0%) | 0% | 0 | Common Stock | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 6.98 per share. | 04 Mar 2025 | 41,600 | 395,788 (0%) | 0% | 7.0 | 290,368 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 6.99 per share. | 04 Mar 2025 | 3,065 | 392,723 (0%) | 0% | 7.0 | 21,424 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 199,549 | 199,549 | - | - | Stock Option (right to buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 132,979 | 356,805 (0%) | 0% | 0 | Common Stock | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 3.44 per share. | 04 Mar 2024 | 18,644 | 327,415 (0%) | 0% | 3.4 | 64,135 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 3.43 per share. | 04 Mar 2024 | 10,746 | 346,059 (0%) | 0% | 3.4 | 36,859 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 199,549 | 199,549 | - | - | Stock Option (right to buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 132,979 | 235,575 (0%) | 0% | 0 | Common Stock | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 8.57 per share. | 06 Mar 2023 | 11,749 | 223,826 (0%) | 0% | 8.6 | 100,689 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 205,931 | 205,931 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 82,372 | 105,266 (0%) | 0% | 0 | Common Stock | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 04 Mar 2022 | 2,670 | 102,596 (0%) | 0% | 12.0 | 32,067 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.71 per share. | 15 Mar 2021 | 1,354 | 24,248 (0%) | 0% | 31.7 | 42,935 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 1,354 | 47,396 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 41.85 per share. | 15 Mar 2021 | 1,014 | 22,894 (0%) | 0% | 41.9 | 42,436 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 41.22 per share. | 15 Mar 2021 | 340 | 23,908 (0%) | 0% | 41.2 | 14,015 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 57,234 | 57,234 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 22,894 | 22,894 (0%) | 0% | 0 | Common Stock | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 57.57 per share. | 01 Mar 2021 | 6,210 | 561 (0%) | 0% | 57.6 | 357,510 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Mar 2021 | 2,604 | 5,208 (0%) | 0% | 6.5 | 17,056 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Mar 2021 | 2,604 | 2,604 (0%) | 0% | 6.5 | 17,056 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 2,604 | 49,480 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 2,604 | 20,834 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 01 Mar 2021 | 1,563 | 6,771 (0%) | 0% | 7.3 | 11,363 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 1,563 | 34,375 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 58.17 per share. | 01 Mar 2021 | 561 | 0 (0%) | 0% | 58.2 | 32,633 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2021 | 416 | 834 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 61.20 per share. | 19 Feb 2021 | 416 | 0 (0%) | 0% | 61.2 | 25,459 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.27 per share. | 19 Feb 2021 | 416 | 416 (0%) | 0% | 6.3 | 2,608 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 16,250 | 48,750 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.71 per share. | 16 Feb 2021 | 16,250 | 16,250 (0%) | 0% | 31.7 | 515,288 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 65.29 per share. | 16 Feb 2021 | 9,528 | 0 (0%) | 0% | 65.3 | 622,083 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 63.42 per share. | 16 Feb 2021 | 5,022 | 11,228 (0%) | 0% | 63.4 | 318,495 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 64.59 per share. | 16 Feb 2021 | 1,700 | 9,528 (0%) | 0% | 64.6 | 109,803 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 55.61 per share. | 01 Feb 2021 | 6,470 | 300 (0%) | 0% | 55.6 | 359,797 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 2,604 | 23,438 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 2,604 | 52,084 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Feb 2021 | 2,604 | 5,208 (0%) | 0% | 6.5 | 17,056 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Feb 2021 | 2,604 | 2,604 (0%) | 0% | 6.5 | 17,056 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 1,562 | 35,938 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 01 Feb 2021 | 1,562 | 6,770 (0%) | 0% | 7.3 | 11,356 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 56.41 per share. | 01 Feb 2021 | 300 | 0 (0%) | 0% | 56.4 | 16,923 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 417 | 1,250 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.27 per share. | 19 Jan 2021 | 417 | 417 (0%) | 0% | 6.3 | 2,615 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 69.00 per share. | 19 Jan 2021 | 417 | 0 (0%) | 0% | 69 | 28,773 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 57.82 per share. | 04 Jan 2021 | 3,800 | 762 (0%) | 0% | 57.8 | 219,716 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 04 Jan 2021 | 2,604 | 5,208 (0%) | 0% | 6.5 | 17,056 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 04 Jan 2021 | 2,604 | 2,604 (0%) | 0% | 6.5 | 17,056 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 2,604 | 54,688 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 2,604 | 26,042 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 56.12 per share. | 04 Jan 2021 | 2,209 | 4,562 (0%) | 0% | 56.1 | 123,969 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 04 Jan 2021 | 1,563 | 6,771 (0%) | 0% | 7.3 | 11,363 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 1,563 | 37,500 | - | - | Common Stock (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 58.63 per share. | 04 Jan 2021 | 495 | 267 (0%) | 0% | 58.6 | 29,022 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 59.46 per share. | 04 Jan 2021 | 267 | 0 (0%) | 0% | 59.5 | 15,876 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.27 per share. | 21 Dec 2020 | 417 | 417 (0%) | 0% | 6.3 | 2,615 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2020 | 417 | 1,667 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 59.14 per share. | 21 Dec 2020 | 417 | 0 (0%) | 0% | 59.1 | 24,661 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 49.43 per share. | 01 Dec 2020 | 3,693 | 0 (0%) | 0% | 49.4 | 182,545 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 48.20 per share. | 01 Dec 2020 | 3,077 | 3,693 (0%) | 0% | 48.2 | 148,311 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Dec 2020 | 2,604 | 2,604 (0%) | 0% | 6.5 | 17,056 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 2,604 | 57,292 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 2,604 | 28,646 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Dec 2020 | 2,604 | 5,208 (0%) | 0% | 6.5 | 17,056 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 1,562 | 39,063 | - | - | Common Stock (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 01 Dec 2020 | 1,562 | 6,770 (0%) | 0% | 7.3 | 11,356 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 48.86 per share. | 19 Nov 2020 | 416 | 0 (0%) | 0% | 48.9 | 20,326 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Nov 2020 | 416 | 2,084 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.27 per share. | 19 Nov 2020 | 416 | 416 (0%) | 0% | 6.3 | 2,608 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 45.47 per share. | 02 Nov 2020 | 5,698 | 1,074 (0%) | 0% | 45.5 | 259,088 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 02 Nov 2020 | 2,605 | 2,605 (0%) | 0% | 6.6 | 17,063 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2020 | 2,605 | 31,250 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2020 | 2,604 | 59,896 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 02 Nov 2020 | 2,604 | 5,209 (0%) | 0% | 6.5 | 17,056 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2020 | 1,563 | 40,625 | - | - | Common Stock (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 02 Nov 2020 | 1,563 | 6,772 (0%) | 0% | 7.3 | 11,363 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 46.14 per share. | 02 Nov 2020 | 1,074 | 0 (0%) | 0% | 46.1 | 49,554 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2020 | 417 | 2,500 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.27 per share. | 19 Oct 2020 | 417 | 417 (0%) | 0% | 6.3 | 2,615 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 51.25 per share. | 19 Oct 2020 | 417 | 0 (0%) | 0% | 51.2 | 21,371 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 48.46 per share. | 01 Oct 2020 | 5,878 | 893 (0%) | 0% | 48.5 | 284,848 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Oct 2020 | 2,605 | 5,209 (0%) | 0% | 6.6 | 17,063 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2020 | 2,605 | 62,500 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Oct 2020 | 2,604 | 2,604 (0%) | 0% | 6.5 | 17,056 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2020 | 2,604 | 33,855 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 01 Oct 2020 | 1,562 | 6,771 (0%) | 0% | 7.3 | 11,356 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2020 | 1,562 | 42,188 | - | - | Common Stock (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 49.26 per share. | 01 Oct 2020 | 893 | 0 (0%) | 0% | 49.3 | 43,989 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.27 per share. | 21 Sep 2020 | 417 | 417 (0%) | 0% | 6.3 | 2,615 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 45.51 per share. | 21 Sep 2020 | 417 | 0 (0%) | 0% | 45.5 | 18,978 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2020 | 417 | 2,917 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 41.28 per share. | 01 Sep 2020 | 6,471 | 300 (0%) | 0% | 41.3 | 267,123 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Sep 2020 | 2,604 | 5,208 (0%) | 0% | 6.5 | 17,056 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 2,604 | 65,105 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 2,604 | 36,459 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Sep 2020 | 2,604 | 2,604 (0%) | 0% | 6.5 | 17,056 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 1,563 | 43,750 | - | - | Common Stock (Right to Buy) | |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 01 Sep 2020 | 1,563 | 6,771 (0%) | 0% | 7.3 | 11,363 | Common Stock |
| Adaptive Biotechnologies Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 41.75 per share. | 01 Sep 2020 | 300 | 0 (0%) | 0% | 41.8 | 12,525 | Common Stock |